Doctor warns of six risks linked to stopping GLP-1 drugs
Physician Frank Dumont warned that discontinuing GLP-1 weight-loss medications such as Ozempic, Wegovy or Zepbound can trigger six health risks, including weight regain, loss of muscle mass and worsening metabolic markers, according to a statement from Guy’s and St Thomas’ NHS Foundation Trust in London. He said the findings underscore the need for careful management when patients stop the drugs.
An observational analysis of more than 80,000 Italian patients with type-2 diabetes, published in Lancet Regional Health and reported by The Times, found that stopping GLP-1 therapy was associated with roughly double the risk of heart attack, stroke or death, independent of changes in weight or blood-sugar levels. Global News added that the elevated risk was especially pronounced among patients with obesity.
